Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF), adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea, and adults and children aged 12 years and older with steroid-refractory acute or chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy.
The approval was based on a clinical study demonstrating that a single 55 mg Jakafi XR tablet taken once daily (QD) is bioequivalent to a single 25 mg Jakafi immediate-release (IR) tablet taken twice daily (BID). Jakafi XR will be available for pharmacy orders beginning May 8.
INCY closed Friday's regular trading at $96.91 or up $1.64 or 1.72%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.